ClinicalTrials.gg
CompletedNCT01145859Updated Aug 6, 2015

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

A Phase 1 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thrombosis and Pediatrics, sponsored by Bayer. Completed at 36 sites in 10 countries. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2015-08-06.

Sponsored by Bayer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
30th of 36
59 · median 120
Started
2010
the only one that year
Phase 1
5 of 36
none open now
Registered
5th of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 30th largest by enrollment, is the only one that started in 2010, is one of 5 in phase 1, and was the 5th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The first study with rivaroxaban in pediatric subjects is a Phase I study, where the pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to confirm that the exposure is comparable to adults. This study is a single dose study with multiple PK/PD measurements in pediatric subjects at the end of their Venous Thromboembolism (VTE) treatment.

03

Conditions studied

  • Venous Thrombosis
  • Pediatrics

Browse trials for

Keywords

  • Venous Thrombosis
  • Pediatrics
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric subjects > 6 months and \< 18 years of age at the time of administration of study drug.
  • Patients who have completed treatment of VTE, but are considered to have risk for recurrence of VTE

Exclusion criteria

Exclusion Criteria:

  • Any major or bleeding during prior VTE treatment
  • Abnormal coagulation tests within 7 days prior to study drug administration
  • Severe renal impairment
  • Planned invasive procedures prior to or after 24 hours of study drug administration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameters (AUC and Cmax)

    Time frame: From Day 1 to Day 2

  2. Pharmacodynamics parameters (PT, aPTT and anti-factor Xa)

    Time frame: From Day 1 to Day 2

Secondary outcomes

  1. Safety and tolerability of rivaroxaban in pediatric subjects

    Time frame: Day 1, day 2 plus 7 days follow up

07

Study locations

36 sites
  • Little Rock, Arkansas 72202-3500, United States
  • Los Angeles, California 90027-6089, United States
  • Los Angeles, California 90095, United States
  • Orange, California 92868, United States
  • Gainesville, Florida 32610, United States
  • St. Petersburg, Florida 33701, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Indianapolis, Indiana 46260, United States
  • Detroit, Michigan 48201-2196, United States
  • New Hyde Park, New York 11040, United States
  • Chapel Hill, North Carolina 27514, United States
  • Durham, North Carolina 27710, United States
  • Cleveland, Ohio 44106-6007, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Brisbane, Queensland 4029, Australia
  • Parkville, Victoria 3052, Australia
  • Linz, 4020, Austria
  • Wien, 1090, Austria
  • Edmonton, Alberta T6G 1C9, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • CLERMONT-FERRAND Cedex 1, 63003, France
  • Montpellier, 34059, France
  • Paris, 75015, France
  • TOULOUSE Cedex 9, 31059, France
  • Lübeck, Schleswig-Holstein 23538, Germany
  • Crumlin, Dublin 12, Ireland
  • Jerusalem, 9112001, Israel
  • Tel Hashomer, 5262000, Israel
  • Genova, 16147, Italy
  • Milano, 20122, Italy
  • Pavia, 27100, Italy
  • Torino, 10126, Italy
  • Basel, Basel-Stadt 4056, Switzerland
08

References and documents

Publications

  • Willmann S, Thelen K, Kubitza D, Lensing AWA, Frede M, Coboeken K, Stampfuss J, Burghaus R, Muck W, Lippert J. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thromb J. 2018 Dec 4;16:32. doi: 10.1186/s12959-018-0185-1. eCollection 2018. PubMed 30534008 ↗
  • Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandao LR, Monagle P, Male C, Chan A, Kennet G, Martinelli I, Saracco P, Lensing AWA. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018 Dec 4;16:31. doi: 10.1186/s12959-018-0186-0. eCollection 2018. PubMed 30534007 ↗
  • Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, Siegmund HU, Thelen K, Muck W. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet. 2014 Jan;53(1):89-102. doi: 10.1007/s40262-013-0090-5. PubMed 23912563 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2010
First posted
Jun 17, 2010
Start
Nov 2010
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Aug 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01145859
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 17, 2010
Start date
Nov 2010
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Aug 6, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion